This may explain why in studies examining BCRP expression, increased ABC transporter levels were not seen in BC patients who received only three cycles of preoperative anthracycline-based therapy compared with chemo-naïve patients (Faneyte et al, 2002). This evidence concerns the gene ABCG2 and breast cancer.